









市场行情
/
股票
/
nasdaq-crvo
/

CervoMed Inc

CRVO

7.600USD

-0.300-3.80%

收盘 12/19, 16:00（美东）报价延迟15分钟

70.32M总市值

亏损市盈率 TTM



CervoMed Inc

7.600

-0.300-3.80%

概览公司财务分析

概览

公司

财务

分析

关于 CervoMed Inc 公司

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

CervoMed Inc简介



公司代码CRVO

公司名称CervoMed Inc

上市日期Nov 09, 2016

CEOAlam (John J)

员工数量15

证券类型Ordinary Share

年结日Nov 09

公司地址20 Park Plaza, Suite 424

城市BOSTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02116

电话16177444400

网址https://cervomed.com/

公司代码CRVO

上市日期Nov 09, 2016

CEOAlam (John J)

CervoMed Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Joshua S. Boger, Ph.D.

Independent Chairman of the Board

1.06M

Mr. John J. Alam, M.D.

President, Chief Executive Officer, Director

753.29K

+3.08%

Mr. Jeffrey V. (Jeff) Poulton

Independent Director

16.44K

Ms. Kelly Blackburn

Executive Vice President - Clinical Development

13.67K

Ms. Jane H. Hollingsworth, M.D.

Independent Director

899.00

Mr. David Quigley

Director

Mr. William R. Elder

Chief Financial Officer, General Counsel, Corporate Secretary

Dr. Marwan Noel Sabbagh, M.D.

Independent Director

Dr. Claudia Ordonez, M.D.

Senior Vice President - Medical Science

Dr. Marco Verwijs, Ph.D.

Executive Vice President - Technical Operations

名称

名称/职务

职务

持股

持股变动

Dr. Joshua S. Boger, Ph.D.

Independent Chairman of the Board

1.06M

Mr. John J. Alam, M.D.

President, Chief Executive Officer, Director

753.29K

+3.08%

Mr. Jeffrey V. (Jeff) Poulton

Independent Director

16.44K

Ms. Kelly Blackburn

Executive Vice President - Clinical Development

13.67K

Ms. Jane H. Hollingsworth, M.D.

Independent Director

899.00

Mr. David Quigley

Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Boger (Joshua S)

11.43%

AWM Investment Company, Inc.

9.33%

Gregoire (Sylvie L.)

8.14%

Alam (John J)

8.14%

Morgan Stanley & Co. LLC

4.43%

其他

58.53%

持股股东

占比

Boger (Joshua S)

11.43%

AWM Investment Company, Inc.

9.33%

Gregoire (Sylvie L.)

8.14%

Alam (John J)

8.14%

Morgan Stanley & Co. LLC

4.43%

其他

58.53%

股东类型

持股股东

占比

Individual Investor

32.17%

Investment Advisor/Hedge Fund

11.21%

Investment Advisor

6.37%

Research Firm

4.45%

Hedge Fund

1.42%

其他

44.38%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

123

2.18M

45.61%

2025Q3

124

2.18M

46.47%

-3.07K

2025Q2

112

2.18M

47.13%

-111.10K

2025Q1

106

2.29M

39.48%

-1.15M

2024Q4

1.50M

41.86%

-2.03M

2024Q3

3.52M

43.30%

+50.30K

2024Q2

3.46M

36.20%

+585.47K

2024Q1

2.52M

7.33%

+2.06M

2023Q4

327.50K

7.25%

-36.20K

2023Q3

363.70K

2.81%

+241.80K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Boger (Joshua S)

1.06M

11.43%

Apr 24, 2025

AWM Investment Company, Inc.

863.20K

9.33%

Jun 30, 2025

Gregoire (Sylvie L.)

730.79K

7.9%

-1.25K

-0.17%

Apr 24, 2025

Alam (John J)

730.79K

7.9%

+1.25K

+0.17%

Apr 24, 2025

Morgan Stanley & Co. LLC

371.23K

4.01%

+240.63K

+184.25%

Jun 30, 2025

Zavrl (Frank E.)

353.01K

3.82%

Apr 24, 2025

The Vanguard Group, Inc.

340.02K

3.67%

-38.64K

-10.21%

Jun 30, 2025

Millennium Management LLC

76.08K

0.82%

+76.08K

Jun 30, 2025

Geode Capital Management, L.L.C.

54.26K

0.59%

-62.23K

-53.42%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

97.58K

1.05%

-223.90K

-69.65%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.01%

iShares Russell 2000 Growth ETF

Global X Russell 2000 ETF

Proshares Ultra Russell 2000

ProShares UltraPro Russell2000

iShares Health Innovation Active ETF

Goldman Sachs ActiveBeta US Small Cap Equity ETF

iShares Russell 2000 ETF

ProShares Hedge Replication ETF

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

占比0.01%

iShares Russell 2000 Growth ETF

占比0%

Global X Russell 2000 ETF

占比0%

Proshares Ultra Russell 2000

占比0%

ProShares UltraPro Russell2000

占比0%

iShares Health Innovation Active ETF

占比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0%

iShares Russell 2000 ETF

占比0%

ProShares Hedge Replication ETF

占比0%

Avantis US Small Cap Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Aug 16, 2023

Merger

1.5→1

Aug 16, 2023

Merger

1.5→1

Aug 16, 2023

Merger

1.5→1

Aug 16, 2023

Merger

1.5→1

Apr 18, 2022

Merger

50→1

Apr 18, 2022

Merger

50→1

公告日期

类型

比率

Aug 16, 2023

Merger

1.5→1

Aug 16, 2023

Merger

1.5→1

Aug 16, 2023

Merger

1.5→1

Aug 16, 2023

Merger

1.5→1

Apr 18, 2022

Merger

50→1

Apr 18, 2022

Merger

50→1

Apr 18, 2022

Merger

50→1

Apr 18, 2022

Merger

50→1

常见问题

CervoMed Inc的前五大股东是谁？



CervoMed Inc 的前五大股东如下：
Boger (Joshua S)持有股份：1.06M，占总股份比例：11.43%。
AWM Investment Company, Inc.持有股份：863.20K，占总股份比例：9.33%。
Gregoire (Sylvie L.)持有股份：730.79K，占总股份比例：7.90%。
Alam (John J)持有股份：730.79K，占总股份比例：7.90%。
Morgan Stanley & Co. LLC持有股份：371.23K，占总股份比例：4.01%。